Evaluation of the Anticaries Efficacy of Dentifrice Formulations Using an In-situ Model

Sponsor
Procter and Gamble (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT06140758
Collaborator
(none)
12
1
6
4.5
2.7

Study Details

Study Description

Brief Summary

The primary objective is to compare the remineralization and demineralization inhibition potential of early subsurface carious lesions in enamel in situ after rinsing with six different aqueous slurries of toothpaste formulations.

Condition or Disease Intervention/Treatment Phase
  • Drug: Oral-B 1450 ppm Fluoride (1.16% sodium monofluorophosphate) Dentifrice
  • Drug: Colgate 1450 ppm Fluoride (1.16% sodium monofluorophosphate)Dentifrice
  • Drug: Toms of Maine 0 ppm Fluoride Dentifrice
  • Drug: Colgate 1450 ppm Fluoride (1.1% sodium monofluorophosphate) Dentifrice
  • Drug: 1500 ppm MFP/CaCO3 1.16% sodium monofluorophosphate) Dentifrice
  • Drug: 1100 ppm (0.454% Stannous fluoride) Dentifrice
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
12 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Evaluation of the Anticaries Efficacy of Various Dentifrice Formulations Using an In-situ Model
Actual Study Start Date :
Jul 31, 2023
Anticipated Primary Completion Date :
Dec 14, 2023
Anticipated Study Completion Date :
Dec 14, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Oral-B 1450 ppm Fluoride (1.16% sodium monofluorophosphate) Dentifrice

Drug: Oral-B 1450 ppm Fluoride (1.16% sodium monofluorophosphate) Dentifrice
Each subject will use this product during one of the six treatment periods in the crossover study design.

Active Comparator: Colgate 1450 ppm Fluoride (1.16% sodium monofluorophosphate)Dentifrice

Drug: Colgate 1450 ppm Fluoride (1.16% sodium monofluorophosphate)Dentifrice
Each subject will use this product during one of the six treatment periods in the crossover study design.

Sham Comparator: Toms of Maine 0 ppm Fluoride Dentifrice

Drug: Toms of Maine 0 ppm Fluoride Dentifrice
Each subject will use this product during one of the six treatment periods in the crossover study design.

Active Comparator: Colgate 1450 ppm Fluoride (1.1% sodium monofluorophosphate) Dentifrice

Drug: Colgate 1450 ppm Fluoride (1.1% sodium monofluorophosphate) Dentifrice
Each subject will use this product during one of the six treatment periods in the crossover study design.

Active Comparator: 1500 ppm MFP/CaCO3 1.16% sodium monofluorophosphate) Dentifrice

Drug: 1500 ppm MFP/CaCO3 1.16% sodium monofluorophosphate) Dentifrice
Each subject will use this product during one of the six treatment periods in the crossover study design.

Active Comparator: 1100 ppm (0.454% Stannous fluoride) Dentifrice

Drug: 1100 ppm (0.454% Stannous fluoride) Dentifrice
Each subject will use this product during one of the six treatment periods in the crossover study design.

Outcome Measures

Primary Outcome Measures

  1. Mineral Density [14 days]

    The percent mineral profile of each enamel/dentinel slab's demineralized control and remineralized/treated lesion, obtained from the microdensitometry analysis, will be compared with the median sound enamel percent mineral profile of the same section. A negative value indicates mineral has been lost and, therefore, the lesion has progressed, whereas a positive value indicates mineral has been gained and, therefore, the lesion has regressed.

  2. Scanning Electron Microscopy (SEM) [14 days]

    SEM imaging and SEM-EDS analysis will be conducted on TMR sections and whole sections of dentine lesions treated in situ to assess the occlusion of dentine tubules and distribution of elements within the lesions following the experiment.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Be 18-75 years of age.

  • Provide written informed consent prior to participation and be given a signed copy of the informed consent form.

  • Be in good general health based on medical/dental history and oral exam.

  • Have no history of adverse or allergic reactions to tin or tin-containing products.

  • Agree not to participate in any other oral study for the study duration.

  • Have a reasonable functional dentition as determined by the oral examiner and sufficient teeth to support the fabricated dental appliance.

  • Be willing to participate in the study, able to follow the study directions, successfully tolerate/perform all study procedures, and willing to return for all specified visits at their appointed time.

  • Be willing to refrain from using non-study dentifrice, mouth rinse, chewing gum, and other non-study oral care products during the study.

  • Be willing to postpone all elective dental procedures until the study has been completed.

  • Be willing to refrain from using calcium chews while using the test products.

  • Be willing and able to refrain from wearing a nightguard (occlusal splint) for the entire course of the study (for nightguard wearers only).

  • Ability to understand, and ability to read and sign, the informed consent form.

  • Have at least 22 natural teeth.

  • Have a gum-stimulated whole salivary flow rate ≥ 1.0 ml/minute and unstimulated whole salivary flow rate ≥ 0.2 ml/minute.

Exclusion Criteria:

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Melbourne Melbourne Australia

Sponsors and Collaborators

  • Procter and Gamble

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Procter and Gamble
ClinicalTrials.gov Identifier:
NCT06140758
Other Study ID Numbers:
  • 2022085
First Posted:
Nov 20, 2023
Last Update Posted:
Nov 20, 2023
Last Verified:
Nov 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 20, 2023